Aspirin in people with dementia, long-term benefits, and harms: a systematic review Katrina A. S. DavisDelia BisharaRobert J. Stewart Review Open access 22 January 2021 Pages: 943 - 954
Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease Amanda R. BuckallewKatie B. TellorAnastasia L. Armbruster Clinical Trial 15 January 2021 Pages: 955 - 960
Calcineurin inhibitor–associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China Pan Kun-mingChen CanLi Xiao-yu Clinical Trial 23 January 2021 Pages: 961 - 969
Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia Takahiro SuzukiTomohiro HiguchiTakahisa Furuta Pharmacodynamics 31 May 2021 Pages: 971 - 978
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs Perrine CourletMonia GuidiChantal Csajka Pharmacokinetics and Disposition Open access 16 January 2021 Pages: 979 - 987
Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment Wanhong WuMeng KeCuihong Lin Pharmacokinetics and Disposition 15 January 2021 Pages: 989 - 998
Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model Xurui GuMin ZhuBoting Zhou Pharmacokinetics and Disposition 10 January 2021 Pages: 999 - 1009
Pharmacological evaluation of prophylactic anti-microbial use in laparoscopic cholecystectomy; an open labelled study evaluating the concentrations of single dose intravenous ceftriaxone at serum and tissue level Sheikh SalimMalik Neeraj KumarGirish Gulab Meshram Pharmacokinetics and Disposition 25 January 2021 Pages: 1011 - 1016
Correction to: Pharmacological evaluation of prophylactic anti-microbial use in laparoscopic cholecystectomy; an open labelled study evaluating the concentrations of single dose intravenous ceftriaxone at serum and tissue level Salim SheikhNeeraj Kumar MalikGirish Gulab Meshram Correction 21 May 2021 Pages: 1017 - 1017
Maternal paracetamol intake and fetal ductus arteriosus constriction/closure: comprehensive signal evaluation using the Austin Bradford Hill criteria Manfred HaubenStephen BaiVincent P. Zucal Pharmacoepidemiology and Prescription 07 January 2021 Pages: 1019 - 1028
Ivabradine use in pregnant women—treatment indications and pregnancy outcome: an evaluation of the German Embryotox database Maria HoeltzenbeinMarie-Louise LehmannChristof Schaefer Pharmacoepidemiology and Prescription Open access 26 January 2021 Pages: 1029 - 1037
Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study Nayeon AhnStefan FrenzelIna-Maria Rückert-Eheberg Pharmacoepidemiology and Prescription Open access 13 January 2021 Pages: 1039 - 1048
Association between newly initiated thiazide diuretics and hospitalization due to hyponatremia Buster MannheimerCecilia Fahlén BerghJonatan D. Lindh Pharmacoepidemiology and Prescription Open access 15 January 2021 Pages: 1049 - 1055
Removal of the EMA orphan designation upon request of the sponsor: cui prodest? Nicola MontanaroGiulia BonaldoDomenico Motola Pharmacoepidemiology and Prescription 26 January 2021 Pages: 1057 - 1063
Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab Benjamin WuStephanie N. LiuRene Bruno Letter to the Editor 07 January 2021 Pages: 1065 - 1066
Authors’ reply to letters to the editor “model-based simulation to support the extended dosing regimens of atezolizumab” Chen-Hsi ChouLi-Feng Hsu Letter to the Editor 25 November 2020 Pages: 1067 - 1068
Blinding, pragmatism, and the PRECIS-2 tool for designing and assessing randomized trials Merrick ZwarensteinAlison Howie Letter to the Editor 04 January 2021 Pages: 1069 - 1070
Pragmatic trials, blinding, placebos, and the usefulness of the PRECIS-2 tool Rafael Dal-Ré Letter to the Editor 13 January 2021 Pages: 1071 - 1072
Liver injury during rivaroxaban treatment in a patient with AL amyloidosis Alan MarrinanL. ShackletonJ. Quinn Letter to the Editor 11 January 2021 Pages: 1073 - 1076
Correction to: Effects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center Yuka KatoAsuna SendaTakaki Toda Correction Open access 23 January 2021 Pages: 1077 - 1077
